Biohaven Stock Price, News & Analysis

On July 29, 2021, Biohaven Pharmaceuticals (NYSE:BHVN) announced that its medication, Nurtec® ODT (rimegepant), is the official migraine partner of the Big Machine Music City Grand Prix. The race will take place in Nashville on August 8, 2021, with Romain Grosjean driving the No. 51 IndyCar. Nurtec ODT is notable for being the first drug approved by the FDA to both treat and prevent migraine attacks. This partnership aims to raise awareness about migraines and highlight the benefits of Nurtec ODT, which affects nearly 40 million Americans.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will report its second quarter 2021 financial results on August 9, 2021, at 8:30 a.m. ET. The earnings call will provide insights into the quarter ended June 30, 2021, along with a review of recent achievements and future milestones. Biohaven specializes in innovative therapies for neurological and neuropsychiatric diseases, including the FDA-approved NURTEC ODT for migraine treatment. Investors can access the call via phone or webcast through Biohaven's website.

Biohaven Pharmaceutical reported preliminary net product revenue of $93 million for NURTEC ODT in Q2 2021, surpassing expectations. Over 750,000 prescriptions have been filled since launch, showing robust growth. NURTEC ODT, the first dual-therapy migraine medication, is approved for both acute and preventive treatment. CEO Vlad Coric emphasized the medication's significant impact on patient care, while CCO BJ Jones highlighted positive feedback from clinicians and patients. The company anticipates continued growth in the migraine treatment market, benefiting approximately 40 million U.S. migraine sufferers.

Sosei Group Corporation announced the dosing of the first healthy subject with HTL0022562 (BHV3100) in a Phase 1 trial. This double-blind, placebo-controlled study will assess the safety and pharmacokinetics of the drug in 88 participants in the UK, expected to complete in 2022. This milestone marks the 10th drug candidate from Sosei's SBDD platform to enter clinical development. Under its collaboration with Biohaven, Sosei will receive milestone payments and funding for the trial while Biohaven leads future studies.

Biohaven Pharmaceutical (NYSE: BHVN) announces the appointment of Kishen Mehta to its Board of Directors. Mehta, a Portfolio Manager at Suvretta Capital, brings 15 years of experience in the financial industry and previously served as a strategic advisor to Biohaven. His expertise will support the company’s goal of becoming a leading biopharmaceutical entity. Biohaven continues to expand its CGRP migraine franchise and advance late-stage programs targeting neurological diseases. The company’s innovative portfolio includes FDA-approved NURTEC® ODT.

Biohaven Pharmaceuticals (NYSE: BHVN) celebrated the FDA approval of its migraine treatment by ringing the opening bell at the New York Stock Exchange on June 8, 2021. This event coincided with Migraine and Headache Awareness Month, highlighting the significance of their breakthrough medication, which is the first and only approved solution for treating and preventing migraines. The company aims to support the migraine community, reflecting its commitment to addressing this prevalent health issue.

Biohaven Pharmaceutical Holding Company (NYSE: BHVN) announced its participation in the 63rd Annual Scientific Meeting of the American Headache Society from June 3-6, 2021, showcasing 19 abstracts including a late-breaking presentation on Nurtec ODT (rimegepant). The FDA approved Nurtec ODT for preventive migraine treatment on May 27. Clinical data presented indicate a significant reduction in monthly migraine days and improved quality of life for patients, especially those who failed prior treatments. Additionally, a Phase 2/3 study of intranasal zavegepant demonstrated promising results for acute migraine treatment.

Biohaven Pharmaceutical announced the FDA approval of NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine, marking it as the first oral CGRP antagonist to receive such approval. This new label allows for up to 18 doses per month, offering both acute and preventive therapy. The approval significantly expands the market potential for NURTEC ODT, benefiting the approximately 95% of U.S. migraine patients with fewer than 15 headache days monthly. The medication's novel formulation provides flexible treatment options, covering a substantial unmet need in migraine care.

Biohaven Pharmaceuticals (NYSE:BHVN) announced that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program. This partnership aims to raise awareness for migraines, affecting nearly 40 million Americans. With Romain Grosjean as the driver, Nurtec ODT's branding will be showcased throughout the racing season. The company emphasizes the significance of addressing migraines, a debilitating condition, through strategic partnerships. Biohaven's commitment to innovation in migraine treatment is highlighted as they expand their outreach.